Enhancing Immune Response and Heterosubtypic Protection Ability of Inactivated H7N9 Vaccine by Using STING Agonist as a Mucosal Adjuvant

Influenza vaccines for H7N9 subtype have shown low immunogenicity in human clinical trials. Using novel adjuvants might represent the optimal available option in vaccine development. In this study, we demonstrated that the using of the STING agonist cGAMP as a mucosal adjuvant is effective in enhanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Jian, Liu, Xu-ping, Xiong, Fei-fei, Gao, Fei-xia, Yi, Ying-lei, Zhang, Min, Chen, Ze, Tan, Wen-song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777483/
https://www.ncbi.nlm.nih.gov/pubmed/31611875
http://dx.doi.org/10.3389/fimmu.2019.02274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777483/
https://www.ncbi.nlm.nih.gov/pubmed/31611875
http://dx.doi.org/10.3389/fimmu.2019.02274

Ejemplares similares